Abaloparatide Boosts Alveolar Bone Growth Through FAK Pathway

Posted: September 2, 2025
A study demonstrates that intraoral submucosal injection of abaloparatide (ABL), combined with mechanical force, promotes in situ alveolar bone thickening outside the original compact bone, originating from the periosteum. The focal adhesion (FA) pathway mediates this process, with ABL enhancing cell proliferation, collagen synthesis, and FAK phosphorylation in the alveolar periosteum. In vitro, ABL boosts proliferation, migration, and FAK phosphorylation in periosteal stem cells. The study suggests that abaloparatide, along with mechanical force, enhances alveolar bone formation through FAK-mediated periosteal osteogenesis, offering a potential therapeutic approach for drug-induced in situ alveolar bone augmentation in dentistry.

This article summary was generated by AI. To view the full article, click the link here: https://pubmed.ncbi.nlm.nih.gov/40890141/
Views: 1
Sponsors
Townie Perks
Townie® Poll
Who or what do you turn to for most financial advice regarding your practice?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@farranmedia.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450